Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months
Data strongly supports advancing high dose AURN001 regenerative cell therapy for patients with corneal endothelial disease to pivotal Phase 3 trial in H1 2026 Seattle, WA; Cambridge, MA; Tokyo, Japan – 18 October – Aurion Biotech, a clinical-stage regenerative medicine company with a mission to restore vision to millions of patients, today announced positive 12-month results from […]